SCHEMBL6323341

SCHEMBL6323341

CC(CCc1ccccc1)NC(=O)c1c(-c2ccc(-c3cccc(Cl)c3)o2)noc1N

nearest known ligand 0.46

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.46
TP53 P04637 3/20 0.46
LMNA P02545 2/20 0.44
HPGD P15428 3/20 0.42
HTT P42858 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
POLB P06746 2/20 0.42
C3AR1 Q16581 1/20 0.42
ERAP2 Q6P179 1/20 0.39
ERAP1 Q9NZ08 1/20 0.39
LNPEP Q9UIQ6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL885511 0.88 C3AR1 (0.41) MAPTTP53HPGDPOLBC3AR1
SCHEMBL6315379 0.87 CYP1A2 (0.48) MAPTHPGDHTTSMN1; SMN2KMT2A
SCHEMBL6315497 0.87 TP53 (0.46) MAPTTP53SMN1; SMN2KMT2AC3AR1
SCHEMBL6316265 0.87 ALDH1A1 (0.42) MAPTTP53HPGDSMN1; SMN2C3AR1
SCHEMBL6323703 0.87 CNR2 (0.43) MAPTTP53POLBC3AR1
SCHEMBL6321134 0.86 CA1 (0.49) MAPTLMNAHPGDHTTSMN1; SMN2
SCHEMBL6323369 0.86 ALDH1A1 (0.41) MAPTTP53HPGDSMN1; SMN2C3AR1
SCHEMBL6318123 0.85 MLLT1 (0.44) MAPTTP53LMNAHPGDSMN1; SMN2
SCHEMBL6317081 0.85 THRB (0.49) KMT2AMEN1
SCHEMBL6319732 0.85 MAPT (0.63) MAPTTP53LMNAHPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
CN-1549714-A Aminoisoxazole derivatives active as kinase inhibitors 2004-11-24 CN claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 MAPT 281/4885TP53 609/4885LMNA 3334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.